scholarly journals Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia

2014 ◽  
Vol 6 ◽  
pp. 1-6
Keyword(s):  
Bacterial Pneumonia ◽  
Ceftaroline Fosamil ◽  
Safety And Efficacy

Day 4 Clinical Response of Ceftaroline Fosamil Versus Ceftriaxone for Community-Acquired Bacterial Pneumonia

2012 ◽  
Vol 20 (4) ◽  
pp. 254-260 ◽  
Author(s):  
Paul B. Eckburg ◽  
H. David Friedland ◽  
Lily Llorens ◽  
Alexander Smith ◽  
Gary W. Witherell ◽  
...  
Keyword(s):  
Clinical Response ◽  
Bacterial Pneumonia ◽  
Ceftaroline Fosamil

Ceftaroline Fosamil for the Treatment of Community-Acquired Bacterial Pneumonia in Elderly Patients

2014 ◽  
Vol 42 (3) ◽  
pp. 109-115 ◽  
Author(s):  
George Udeani ◽  
John Evans ◽  
Phillip Cole ◽  
H. David Friedland
Keyword(s):  
Elderly Patients ◽  
Bacterial Pneumonia ◽  
Ceftaroline Fosamil

scholarly journals Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia

2013 ◽  
Vol 57 (12) ◽  
pp. 6348-6350 ◽  
Author(s):  
Sujata M. Bhavnani ◽  
Jeffrey P. Hammel ◽  
Scott A. Van Wart ◽  
Christopher M. Rubino ◽  
Daniel K. Reynolds ◽  
...  
Keyword(s):  
Steady State ◽  
Bacterial Pneumonia ◽  
Free Drug ◽  
Trial Data ◽  
Phase Iii ◽  
Success Rates ◽  
Dosing Regimen ◽  
Ceftaroline Fosamil ◽  
Phase Iii Trial ◽  
Dosing Interval

ABSTRACTPharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using phase III trial data from patients treated with a ceftaroline fosamil dosing regimen of 600 mg intravenously (i.v.) every 12 h (q12h) for 5 to 7 days for community-acquired bacterial pneumonia (CABP) were conducted. High clinical and microbiological success rates (84.7 and 86.3%, respectively) and percentages of time during the dosing interval that free-drug steady-state concentrations remained above the MIC (f%T>MIC) (98.4% hadf%T>MIC values of ≥63.3) were observed among 124 microbiologically evaluable patients. As a result, significant PK-PD relationships could not be identified. These data provide support for the use of a ceftaroline fosamil dosing regimen of 600 mg i.v. q12h to treat patients with CABP.

Sign in / Sign up

Export Citation Format

Share Document